Cargando…
Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection
The RNA interference (RNAi) drug ARC-520 was shown to be effective in reducing serum hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) in HBeAg-positive patients treated with a single dose of ARC-520 and daily nucleosidic analogue (entecavir). To prov...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794570/ https://www.ncbi.nlm.nih.gov/pubmed/33420293 http://dx.doi.org/10.1038/s41598-020-80594-6 |